Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients

International Journal of Biological Markers

Volumn 27, Issue 4, 2012, Pages

  Chan, Monica S M ^a,b   Wang, Lin ^a,c   Felizola, Saulo J A ^a   Ueno, Takayuki ^d   Toi, Masakazu ^d   Loo, W ^b   Chow, Louis W C ^b   Suzuki, Takashi ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIMED Medical Institute   (Hong Kong)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Aromatase inhibitors; Breast cancer; Cd8+ treg ratio; Immunohistochemistry; Tumor inflammatory lymphocytes

Indexed keywords

CD8 ANTIGEN; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; AROMATASE INHIBITOR; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ARTICLE; BREAST CARCINOMA; BREAT CARCINOMA; CANCER HORMONE THERAPY; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROSCOPY; PATHOLOGY; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; CORE BIOPSY NEEDLE; DISEASE MARKER; SCORING SYSTEM; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; BREAST TUMOR; DRUG EFFECT; GENETICS; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL;

EID: 84872875325     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/JBM.2012.10439     Document Type: Article

References (75)

1. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008; 27: 5904-5912.
2. Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 2009; 15: 1949-1955.
3. Mbeunkui F, Johann DJ Jr. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009; 63: 571-582.
4. Liotta LA, Kohn EC. The microenvironment of the tumourhost interface. Nature 2001; 411: 375-379.
5. Jung YD, Ahmad SA, Liu W, et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol 2002; 12: 105-112.
6. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 2001; 11: 35-40.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
8. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-8.
9. Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ishikura H. Pathophysiology of tumor neovascularization. Vasc Health Risk Manag 2005; 1: 277-90.
10. Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res 2007; 9: 216.
11. Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumours: an overview. Eur J Intern Med 2009; 20: 663-71.
12. Gupta MK, Qin RY. Mechanism and its regulation of tu human mor-induced angiogenesis. World J Gastroenterol 2003; 9: 1144-55.
13. Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008; 130: 1091-103.
14. Folkman J. Tumor angiogenesis. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, eds. Cancer medicine. 5th ed. Ontario (Canada): BC Decker Inc., 2000; 132-152.
15. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431: 405-406.
16. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-345.
17. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell 2007; 12: 300-301.
18. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148.
19. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360.
20. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998.
21. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-365.
22. Liu F, Lang R, Zhao J, et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011; 130: 645-655.
23. Mahmoud SM, Paish EC, Powe DG, et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011; 127: 99-108.
24. Wong PY, Staren ED, Tereshkova N, Braun DP. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. J Surg Res 1998; 76: 95-103.
25. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
26. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666.
27. Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14: 2413-2420.
28. Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004; 4: 408-414.
29. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
30. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007; 13: 108-116.
31. Sakaguchi S, Wing K, Miyara M. Regulatory T cells-a brief history and perspective. Eur J Immunol 2007; 37: S116-S123.
32. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787.
33. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008; 18: 11-8.
34. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167: 1137-1140.
35. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19: 217-223.
36. Woo EY, Yeh H, Chu CS, et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168: 4272-4276.
37. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22: 329-341.
38. Roncador G, Brown PJ, Maestre L, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005; 35: 1681-1691.
39. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-18543.
40. Zeestraten EC, Van Hoesel AQ, Speetjens FM, et al. Foxp3-and CD8-positive infiltrating immune cells together determine clinical outcome in colorectal cancer. Cancer Microenviron 2011 Jul 6. [Epub ahead of print]
41. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
42. Lake RA, Robinson BW. Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer 2005; 5: 397-405.
43. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
44. Demaria S, Volm MD, Shapiro RL, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001; 7: 3025-3030.
45. Ladoire S, Mignot G, Dabakuyo S, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011; 224: 389-400.
46. Sato N, Masuda N, Saji S, et al. Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IIIa breast cancer (JFMC34-0601) [abstract 591]. J Clin Oncol 2009; 27: 15S.
47. Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib antiaromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008, 111: 13-7.
48. Tamaki K, Moriya T, Sato Y, et al. Vasohibin-1 in human 278. breast carcinoma: a potential negative feedback regulator of angiogenesis. Cancer Sci 2009; 100: 88-94.
49. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339.
50. Chan MS, Wang L, Chanplakorn N, et al. Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opin Ther Targets 2012; 16: S69-S78.
51. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474-81.
52. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1;25(1):118-145. Epub 2006 Dec 11.
53. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Proliferation, steroid receptors and clinical/pathobiological response in breast cancer treated with letrozole. Br J Cancer 2006; 94: 1051-1056.
54. Chanplakorn N, Chanplakorn P, Suzuki T, et al. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 2010; 120: 639-648.
55. Yiu CC, Chanplakorn N, Chan MS, et al. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. Anticancer Res 2010; 30: 3465-3472.
56. Generali D, Bates G, Berruti A, et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 2009; 15: 1046-1051.
57. Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 2001; 79: 103-107.
58. Sasano H, Sato S, Ito K, et al. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer 1999; 6: 197-204.
59. Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 2002; 87: 334-338.
60. Miller WR, Anderson TJ, White S, et al. Aromatase inhibi tors: cellular and molecular effects. J Steroid Biochem Mol Biol 2005; 95: 83-89.
61. Miller WR, Larionov A. Molecular effects of oestrogen deprivation in breast cancer. Mol Cell Endocrinol 2011; 340: 127-136.
62. Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003; 63: 8037-8050.
63. Akli S, Bui T, Wingate H, et al. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 2010; 16: 1179-90.
64. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003; 39: 462-468.
65. Miller WR. Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol 2010; 118: 273-276.
66. Dowsett M, Smith IE, Ebbs SR, et al; IMPACT Trialists. Shortterm changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin cancer Res 2005; 11: 951s-8s.
67. Gregory CD, Pound JD. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol 2011; 223: 177-94.
68. Golpon HA, Fadok VA, Taraseviciene-Stewart L, et al. Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J 2004; 18: 1716-8.
69. Ravichandran KS. "Recruitment signals" from apoptotic cells: invitation to a quiet meal. Cell 2003; 113: 817-820.
70. Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006; 11: 1709-1726.
71. Fadok VA, Henson PM. Apoptosis: getting rid of the bodies. Curr Biol 1998; 8: R693-R695.
72. Pham CT, Ley TJ. The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Semin Immunol 1997; 9: 127-133.
73. Prieto GA, Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology 2006; 118: 58-65.
74. Sharma S, Yang SC, Zhu L, et al. Tumor cyclooxygenase-2/ prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005; 65: 5211-5220.
75. Chan MSM, Wang L, Chanplakorn N, et al. Alteration of tumor associated inflammatory cells pre and postneoadjuvant endocrine therapy - a morphological assessment. Proceedings of the 70th Annual Meeting of the Japanese Cancer Association 2011; 278.